Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Get Free Report) shares traded down 6.3% during mid-day trading on Tuesday . The stock traded as low as $14.12 and last traded at $13.80. 1,322,340 shares were traded during trading, a decline of 17% from the average session volume of 1,601,629 shares. The stock had previously closed at $14.73.
Ginkgo Bioworks Stock Performance
The business's 50 day simple moving average is $11.48. The firm has a market cap of $602.10 million, a PE ratio of -0.80 and a beta of 1.16.
Institutional Investors Weigh In On Ginkgo Bioworks
Institutional investors and hedge funds have recently bought and sold shares of the business. PDT Partners LLC acquired a new stake in shares of Ginkgo Bioworks during the 3rd quarter worth approximately $1,199,000. Erste Asset Management GmbH acquired a new stake in shares of Ginkgo Bioworks in the 3rd quarter worth about $4,075,000. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Ginkgo Bioworks in the 3rd quarter worth about $2,282,000. BNP Paribas Financial Markets bought a new stake in Ginkgo Bioworks in the 3rd quarter valued at about $1,287,000. Finally, PFG Investments LLC acquired a new stake in shares of Ginkgo Bioworks in the third quarter valued at approximately $1,541,000. Institutional investors and hedge funds own 78.63% of the company's stock.
About Ginkgo Bioworks
(
Get Free Report)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
Read More
Before you consider Ginkgo Bioworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ginkgo Bioworks wasn't on the list.
While Ginkgo Bioworks currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
